Paediatric adrenocortical tumours are a biologically diverse group of diseases that can be divided into clinically distinct subtypes using proteomic profiling, say German researchers.
Patients with congenital adrenal hyperplasia are significantly more likely to be admitted to hospital and experience severe in-hospital outcomes than people without the condition, especially during the first years of life, highlight Swiss researchers.
International guidance has been published on managing the transition of children with endocrine disorders from paediatric to adult services, and on the use of genetic testing in children with short stature.
We are delighted to welcome you to the 12th Insights into MAnaging Growth for Endocrine nurses (IMAGE) November 2026 Meeting, organised by Springer Health+ IME. This event will be dedicated to the loving memory of Professor Martin Savage and will take place on 5–6 November 2026 in the beautiful and historic city of Seville in Spain.
A European Standard Clinical Practice Guidance has been published in the European Journal of Endocrinology on the diagnosis and treatment of adrenal and extra-adrenal paragangliomas in children and adolescents.
US researchers have created age- and sex-adjusted growth charts for use in children with classic congenital adrenal hyperplasia, reflecting the distinct patterns of height and weight among patients versus the general population.
The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.
Children and young adults with congenital adrenal hyperplasia may be at long-term risk of low bone mineral density, with the greatest risk found in boys and young men, Italian researchers have found.
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
Phase 3 trial findings support the use of an oral corticotropin-releasing factor type 1 receptor antagonist for the treatment of classic congenital adrenal hyperplasia in children with 21-hydroxylase deficiency.
